Citations

Showing 10 of 108162 citations.

Remdesivir: An Antiviral Still Seeking aRaison d'Être
Cummins, Nathan W.

Mayo Clinic

Clinical Infectious Diseases | March 6, 2021 | Volume: 73 | Issue: 10 | Pages: 1857-1859

10.1093/cid/ciab220 | PMID 33749746 Get It

JCN Book Review
Laughlin, Ruple S.

Mayo Clinic

Journal of Clinical Neurophysiology | March 6, 2021 | Volume: 38 | Issue: 3 | Pages: e14-e15

10.1097/wnp.0000000000000837 Get It

Need for Additional Glaucoma Surgery and Complications Following Glaucoma Drainage Device Surgery
Kung, Felix F. , Knier, Kit , Mejía, Camilo A. , Sargent, Jason, Dogahe, Sepideh Jamali, Sabbagh, Nouran, Hodge, David O. , Khanna, Cheryl L. , Knier, Catherine G, Garmany, Armin , Sargent, Jason M, Jamali Dogahe, Sepideh

Mayo Clinic

Journal of Glaucoma | March 6, 2021 | Volume: 30 | Issue: 6 | Pages: 508-514

10.1097/ijg.0000000000001827 | PMID 33675337 Get It

Précis: In this longitudinal study of patients with open-angle (OAG), pseudoexfoliative (PXE), or neovascular glaucoma (NVG) receiving glaucoma drainage devices (GDD), posttube cumulative rates of reoperation, corneal graft, and visually threatening complications (VT-complications) increased beyond 5 years and were not significantly affected by glaucoma type. Purpose: To study the need for additional glaucoma surgery and development of complications after first GDD surgery in eyes with primary OAG, PXE, or NVG glaucoma. Patients and Methods: There were 306 eyes with OAG (n=185), PXE (n=60), or NVG (n=61) glaucoma who received a first GDD between 1996 and 2017. Outcomes including glaucoma reoperation, corneal graft procedure, and VT-complications after GDD were measured. Kaplan-Meier analysis was used to compare cumulative rate of reaching outcomes over time after GDD placement among the 3 glaucoma groups. Results: When comparing the OAG, PXE, and NVG groups, there were no significant differences in post-GDD cumulative rates of reoperation (P=0.33), corneal graft (P=0.26), or VT-complications (P=0.65) over time. For all eyes, the overall cumulative rates for each outcome measure increased beyond 5 years, and specific Kaplan-Meier rates (5-y, 10-y) included: reoperation (16%, 25%), corneal graft (6%, 12%), VT-complications (9%, 14%). When comparing specific GDDs, the Ahmed FP7 had a higher cumulative reoperation rate over time compared with the Baerveldt 350 (P=0.019). Conclusion: Glaucoma type did not significantly affect post-GDD cumulative rates of reoperation, corneal graft, and VT-complication among the OAG, PXE, and NVG groups. For all eyes, cumulative rates of reoperation, corneal graft, and VT-complications increased beyond 5 years. The Ahmed FP7 had a significantly higher cumulative reoperation rate compared with the Baerveldt 350 over time.
Pulmonary Function Changes in the Older adults with and without Metabolic Syndrome
Rangel, Maysa, Moraes-Ferreira, Renilson , Santos‐Dias, Alana, Gabriela-Pereira, Giovana, Freitas, Simone de Oliveira, Araújo-Rosa, Amanda Cristina, Oliveira, Luí­s Henrique Sales , Frison, Claudio Ricardo , Balagopal, Prabhakaran , Vieira, Rodolfo P. , Oliveira‐Junior, Manoel Carneiro , Bachi, André Luís Lacerda , Raju, Raghavan Pillai

Mayo Clinic

No container title available | March 5, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-271946/v1 Get It

Abstract Low-grade inflammation associated with metabolic syndrome (MS) triggers alterations in several organs, but its effects on pulmonary functional and immunological response in older adults are unknown. This cross-sectional study investigated such responses in older adults with and without MS. The study consisted of 77 older adults with MS (68 ± 3 years old) and without MS (67 ± 3 years old). Impulse oscillometry (IOS) was used to evaluate airway and tissue resistance and reactance. Biomarkers of systemic and pulmonary inflammation and fibrosis were studied. Total resistance of respiratory system (R5Hz; p < 0.009), and resistance of proximal (R20Hz; p < 0.001) and distal (R5Hz-R20Hz; p < 0.004) airways were impaired in MS individuals compared to those without MS. The levels of pro-inflammatory (leptin; IL-1beta; IL-8, p < 0.001; TNF-alpha, p < 0.04) and pro-fibrotic (VEGF, p < 0.001) factor increased in MS, while reduced levels of anti-inflammatory cytokines (adiponectin; IL-1ra; IL-10; p < 0.001), and anti-fibrotic (relaxin 1; relaxin 3; Klotho, p < 0.001) factors were found. We conclude that MS accelerates lung function and mechanics impairment in older adults in detriment of an imbalance between pro and anti-inflammatory and fibrotic mediators. Furthermore, this study shows that the lungs also are a target organ in MS, deserving clinical assessment in older adults’ population.
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., Dilling, Thomas J. , Dowell, Jonathan E. , Gettinger, Scott , Gubens, Matthew A. , Hegde, Aparna , Hennon, Mark, Lackner, Rudy P., Leal, Ticiana , Lin, Jules , Martins, Renato , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Lanuti, Michael D. , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 5, 2021 | Volume: 19 | Issue: 3 | Pages: 254-266

10.6004/jnccn.2021.0013 | PMID 33668021 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, Al B. , Al-Hawary, Mahmoud M. , Arain, Mustafa A., Chen, Yi‐Jen , Ciombor, Kristen K. , Cooper, Harry S. , Deming, Dustin A. , Farkas, Linda M., Garrido‐Laguna, Ignacio , Grem, Jean L. , Hecht, J. Randolph, Hoffe, Sarah E. , Hunt, Steven R., Johung, Kimberly L. , Kirilcuk, Natalie, Krishnamurthi, Smitha , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Patel, Hitendra , Pedersen, Katrina S. , Shibata, David , Skibber, John M., Sofocleous, Constantinos T. , Stotsky‐Himelfarb, Eden, Willett, Christopher G. , Gregory, Kristina M., Gurski, Lisa A., Hubbard, Joleen, Meyerhardt, Jeffrey A , Pedersen, Katrina , Venook, Alan P. , Cohen, Stacey A. , Gunn, Andrew, Hubbard, Joleen M. , Miller, Eric D. , Parikh, Aparna R. , Patel, Hitendra, Saltz, Leonard B. , Schneider, Charles John , Stoffel, Elena M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 5, 2021 | Volume: 19 | Issue: 3 | Pages: 329-359

10.6004/jnccn.2021.0012 | PMID 33724754 Get It

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation–positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org . Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship.
Community prevalence, mechanisms and outcome of mitral or tricuspid regurgitation
Cahill, Thomas J. , Prothero, Anthony, Wilson, Jo, Kennedy, Andrew , Brubert, Jacob , Masters, Megan , Newton, James D. , Prendergast, Bernard , Prendergast, Bernard D , Myerson, Saul G , Enriquez-Sarano, Maurice , Dawkins, Sam , Enriquez‐Sarano, Maurice

Mayo Clinic

Heart | March 5, 2021 | Volume: 107 | Issue: 12 | Pages: 1003-1009

10.1136/heartjnl-2020-318482 | PMID 33674352 Get It

Objective The study aims were (1) to identify the community prevalence of moderate or greater mitral or tricuspid regurgitation (MR/TR), (2) to compare subjects identified by population screening with those with known valvular heart disease (VHD), (3) to understand the mechanisms of MR/TR and (4) to assess the rate of valve intervention and long-term outcome. Methods Adults aged ≥65 years registered at seven family medicine practices in Oxfordshire, UK were screened for inclusion (n=9504). Subjects with known VHD were identified from hospital records and those without VHD invited to undergo transthoracic echocardiography (TTE) within the Oxford Valvular Heart Disease Population Study (OxVALVE). The study population ultimately comprised 4755 subjects. The severity and aetiology of MR and TR were assessed by integrated comprehensive TTE assessment. Results The prevalence of moderate or greater MR and TR was 3.5% (95% CI 3.1 to 3.8) and 2.6% (95% CI 2.3 to 2.9), respectively. Primary MR was the most common aetiology (124/203, 61.1%). Almost half of cases were newly diagnosed by screening: MR 98/203 (48.3%), TR 69/155 (44.5%). Subjects diagnosed by screening were less symptomatic, more likely to have primary MR and had a lower incidence of aortic valve disease. Surgical intervention was undertaken in six subjects (2.4%) over a median follow-up of 64 months. Five-year survival was 79.8% in subjects with isolated MR, 84.8% in those with isolated TR, and 59.4% in those with combined MR and TR (p=0.0005). Conclusions Moderate or greater MR/TR is common, age-dependent and is underdiagnosed. Current rates of valve intervention are extremely low.
Potential for selection bias surrounding reporting of benign brain tumors in the United States
Marinelli, John P. , Carlson, Matthew L.

Mayo Clinic

Neuro-Oncology | March 5, 2021 | Volume: 23 | Issue: 6 | Pages: 1037-1038

10.1093/neuonc/noab059 | PMID 33900391 Get It

Assessment of a Polygenic Risk Score for Colorectal Cancer to Predict Risk of Lynch Syndrome Colorectal Cancer
Lai, John , Makalic, Enes , Win, Aung Ko , Winship, Ingrid , Huyghe, Jeroen R. , Peters, Ulrike , Gallinger, Steven , Figueiredo, Jane C. , Pai, Rish K. , Jenkins, Mark A , Makalic, Enes , Winship, Ingrid M , Win, Aung K , Jenkins, Mark A. , Buchanan, Daniel D. , Dite, Gillian S. , Clendenning, Mark , Hayes, Richard B. , Marchand, Loı̈c Le , Newcomb, Polly A. , Church, James M. , Casey, Graham , Hopper, John L.

Mayo Clinic

JNCI Cancer Spectrum | March 5, 2021 | Volume: 5 | Issue: 2 | Pages: No page available

10.1093/jncics/pkab022 | PMID 33928216 Get It

Abstract It was not known whether the polygenic risk scores (PRSs) that predict colorectal cancer could predict colorectal cancer for people with inherited pathogenic variants in DNA mismatch repair genes—people with Lynch syndrome. We tested a PRS comprising 107 established single-nucleotide polymorphisms associated with colorectal cancer in European populations for 826 European-descent carriers of pathogenic variants in DNA mismatch repair genes (293 MLH1, 314 MSH2, 126 MSH6, 71 PMS2, and 22 EPCAM) from the Colon Cancer Family Registry, of whom 504 had colorectal cancer. There was no evidence of an association between the PRS and colorectal cancer risk, irrespective of which DNA mismatch repair gene was mutated, or sex (all 2-sided P &gt; .05). The hazard ratio per standard deviation of the PRS for colorectal cancer was 0.97 (95% confidence interval = 0.88 to 1.06; 2-sided P = .51). Whereas PRSs are predictive of colorectal cancer in the general population, they do not predict Lynch syndrome colorectal cancer.
Incidence of Hip Dysplasia Diagnosis in Young Patients With Hip Pain: A Geographic Population Cohort Analysis
LaPrade, Matthew D. , Melugin, Heath P. , Hale, Rena F. , Leland, Devin P. , Bernard, Christopher D. , Trousdale, Robert T. , Levy, Bruce A. , Krych, Aaron J. , Krych, Aaron J , Sierra, Rafael J.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | March 5, 2021 | Volume: 9 | Issue: 3 | Pages: No page available

10.1177/2325967121989087 | PMID 33748308 Get It

Background: Hip dysplasia is a common source of hip pain and a known cause of early osteoarthritis of the hip. Purpose: To (1) define the population-based incidence of hip dysplasia diagnosis in young patients presenting with hip pain in a large geographically defined cohort, (2) analyze trends regarding presentation and diagnosis of hip dysplasia, and (3) report the rate and type of surgical interventions used to treat this population. Study Design: Cross-sectional study; Level of evidence, 3. Methods: A geographic epidemiological database was queried to identify patients aged 14 to 50 years with hip pain between the years 2000 and 2016. Patient medical records were analyzed, and demographic, imaging, clinical, and treatment history were recorded. Incidence trends were examined by use of linear regression with confidence intervals for age and calendar year. Results: Overall, 1893 patients were included. Of these, 156 patients (196 hips) had a diagnosis of hip dysplasia. The incidence of hip dysplasia diagnosis in patients who reported hip pain was 12.7 per 100,000 person-years. Patients with dysplasia had a mean age of 26.7 ± 9.8 years, while the highest age-adjusted incidence occurred at age 14 to 18 years in both male and female patients. Female patients had double the age-adjusted incidence of male patients (cases per 100,000 person-years: 16.8 [95% CI, 13.9-19.7] vs 8.7 [95% CI, 6.6-10.8]; P < .01). Of the patients who underwent magnetic resonance imaging, 77% had imaging consistent with labral pathology. Patients were treated with physical therapy (67%), intra-articular steroid injection (29%), hip arthroscopy (10%), and periacetabular osteotomy (9%). The use of hip arthroscopy significantly increased over time ( P < .01), whereas the use of steroid injection and periacetabular osteotomy did not ( P < .28 and P < .08, respectively). Conclusion: The incidence of hip dysplasia diagnosis in patients presenting with hip pain was 12.7 per 100,000 person-years. Female patients had twice the age-adjusted incidence of male patients, and the highest age-adjusted incidence occurred in the age range of 14 to 18 years in both sexes. The use of hip arthroscopy to treat patients with hip dysplasia significantly increased over time.